BDBM509848 US11124497, Compound 361::US11312704, Compound 361::US11472793, Compound 361::US11524940, Compound 361

SMILES CC(C)C[C@H](NC(=O)c1cc2c(OC(F)(F)F)cccc2[nH]1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C#N

InChI Key

Data  8 IC50  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 509848   

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50:  83nMAssay Description:The proteolytic activity of the main protease, 3CLpro, of SARS-CoV-2 was monitored using a continuous fluorescence resonance energy transfer (FRET) a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails WIPO WO2021250648

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataEC50:  2.68E+3nMAssay Description:The ability of compounds to prevent SARS-CoV-2 coronavirus-induced cell death or cytopathic effect can be assessed via cell viability, using an assay...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails WIPO WO2021250648

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataEC50: <2.20E+4nMAssay Description:Compounds were assayed using standard methods against multiple coronaviral strains, including HCoV 229E and OC43 strains. The antiviral activity of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.20E+4nMAssay Description:Compounds were assayed using standard methods to assess compound activity and IC50. As an exemplary for assessment of the SARS-COV2 Mpro, the C-His6-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.20E+4nMAssay Description:Compounds were assayed using standard methods to assess compound activity and IC50. As an exemplary for assessment of the SARS-COV2 Mpro, the C-His6-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataEC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods against multiple coronaviral strains, including HCoV 229E and OC43 strains. The antiviral activity of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods against multiple coronaviral strains, including HCoV 229E and OC43 strains. The antiviral activity of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods to assess compound activity and IC50. As an exemplary for assessment of the SARS-COV2 Mpro, the C-His6-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1a(SARS-CoV)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.00E+3nMAssay Description:Compounds are assayed using standard methods to assess compound activity and IC50. As an exemplary for assessment of the SARS-COV2 Mpro, the C-His6-t...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods against multiple coronaviral strains, including HCoV 229E and OC43 strains. The antiviral activity of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(2019-nCoV)
Pfizer

WIPO
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataIC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods to assess compound activity and IC50. As an exemplary for assessment of the SARS-COV2 Mpro, the C-His6-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetReplicase polyprotein 1ab(HCoV-229E)
Pardes Biosciences

US Patent
LigandPNGBDBM509848(US11124497, Compound 361 | US11312704, Compound 36...)
Affinity DataEC50: <2.00E+3nMAssay Description:Compounds were assayed using standard methods against multiple coronaviral strains, including HCoV 229E and OC43 strains. The antiviral activity of c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent